Brind.

Day One Biopharmaceuticals' targeted therapy Ojemda is undergoing study updates, while analysts maintain 'Buy' ratings amid reports that Trump-era tariffs benefit AI stocks.

2 reports, 2 independent Updated Aug 19
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Day One Biopharmaceuticals' targeted therapy Ojemda is undergoing study updates, while analysts maintain 'Buy' ratings amid reports that Trump-era tariffs benefit AI stocks.

Who's involved

What this event is mainly about
Day One Biopharmaceuticals (United States)JPMorgan ChaseDonald Trump

How it developed

Newest first. Tap a step to see who reported it.
  1. Day One's Ojemda study awaits updates as analysts maintain 'Buy' ratings, coinciding with reports on Trump tariffs benefiting AI stocks.1 source
  2. Day One Biopharmaceuticals achieved double-digit revenue growth and cut investment in VRK1 program.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyH.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN) With significant hedge fund interest and a share price under $10, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) sec
  • GuruFocus.comDay One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... Release Date: August 05, 2025 For the complete transcript of the earnings call, please refer to the f